The Food and Drug Administration (FDA) has requested that Congress intervene in the oversight of cannabidiol (CBD) products derived from hemp, citing concerns about the lack of scientific literature on the potential risks associated with long-term use. FDA Commissioner Janet Woodcock also noted that it is unclear how much CBD can be consumed before causing harm.
The FDA's request has been met with both disappointment and support. Industry groups and members of Congress have long sought a resolution to the issue, and now have the opportunity to take up the FDA's call. Despite the FDA's continued efforts to shut down companies that make specific health claims about CBD products, the CBD industry has grown to nearly $6 billion in the past four years and has bipartisan support, increasing the likelihood of legislative action.
Meanwhile, states have taken up CBD legislation, creating a patchwork of laws throughout the country. The question now is how Congress will respond to the FDA's request for intervention. With the potential for a large economic impact, and the need for more research on the safety of CBD products, Congress may soon be taking up the issue.